期刊文献+

前列腺素E1脂微球载体制剂联合西洛他唑治疗下肢动脉硬化闭塞症临床研究 预览 被引量:1

Clinical Study on Prostaglandin E1 Lipid Microsphere Carrier Preparation Combined with Cilostazol in the Treatment of Lower Extremity Arteriosclerosis Obliterans
在线阅读 下载PDF
收藏 分享 导出
摘要 目的探讨前列腺素E1脂微球载体制剂(Lipo-PGE1)联合西洛他唑治疗下肢动脉硬化闭塞症的临床疗效。方法选取医院2016年10月至2017年10月收治的下肢动脉硬化闭塞症患者60例,按随机数字表法分为对照组和联合组,各30例。对照组患者单纯采用西洛他唑治疗,联合组患者采取西洛他唑联合Lipo-PGE1治疗,疗程均为4周。结果联合组治疗总有效率为93.33%,高于对照组的80.00%(P<0.05);治疗后,两组患者C反应蛋白(CRP)、白细胞介素6(IL-6)、肿瘤坏死因子-α(TNF-α)、细胞间黏附分子-1(ICAM-1)、峰值血流速度、血流搏动指数及甲襞微循环积分均较治疗前下降(P<0.05),且联合组上述指标水平均低于对照组(P<0.05);两组踝肱指数(ABI)升高,且联合组高于对照组(P<0.05);两组不良反应发生率及截肢率比较无明显差异(P >0.05)。结论西洛他唑联合Lipo-PGE1治疗下肢动脉硬化闭塞症,效果显著,能显著减轻炎性反应,改善血流动力学,且安全性好。 Objective To investigate the clinical effect of prostaglandin E1 lipid microsphere carrier preparation(Lipo-PGE1)combined with cilostazol in the treatment of lower extremity arteriosclerosis obliterans.Methods Totally 60 patients with lower extremity arteriosclerosis obliterans admitted to our hospital from October 2016 to October 2017 were selected and divided into the control group and the combined group according to the random number table method,30 cases in each group.The patients in the control group were treated with cilostazol alone,while the patients in the combined group were treated with cilostazol combined with Lipo-PGE1.The course of treatment was 4 weeks.Results The total effective rate of the combined group was 93.33%,which was higher than 80.00%of the control group(P<0.05).After treatment,the levels of C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and intercellular adhesion molecule-1(ICAM-1),the peak blood flow velocity,blood flow pulsation index and nail fold microcirculation integral in the two groups were lower than those before treatment(P<0.05),and the above indexes in the combined group were lower than those in the control group(P<0.05).The ankle brachial indexes(ABI)of the two groups were increased,and that of the combined group was higher than that of the control group(P<0.05).There were no significant differences in the incidence rate of adverse reactions and amputation rate between the two groups(P >0.05).Conclusion Cilostazol combined with Lipo-PGE1 in the treatment of lower extremity arteriosclerosis obliterans has a significant effect and safety,which can significantly reduce inflammatory response and improve hemodynamics.
作者 龚亦群 俞志强 洪彪 王暐 王夕栩 董波 GONG Yiqun;YU Zhiqiang;HONG Biao;WANG Wei;WANG Xixu;DONG Bo(Department of General Surgery,Shanghai Tongren Hospital,Shanghai,China 200035)
出处 《中国药业》 CAS 2019年第5期46-48,共3页 China Pharmaceuticals
基金 上海市科学技术委员会科研计划[16401930900]。
关键词 下肢动脉硬化闭塞症 西洛他唑 前列腺素E1脂微球载体制剂 安全性 临床疗效 lower extremity arteriosclerosis obliterans cilostazol prostaglandin E1 lipid microsphere carrier preparation safety clinical effect
作者简介 第一作者:龚亦群,男,大学本科,副主任医师,研究方向为血管外科学,(电子信箱)gyq20170430@163.com;通信作者:俞志强,男,大学本科,副主任医师,研究方向为普外科学,(电子信箱)yzqiang2004@aliyun.com。
  • 相关文献

参考文献13

二级参考文献86

共引文献67

同被引文献9

引证文献1

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈